Reduced vessel density in the superficial and deep plexuses in diabetic retinopathy is associated with structural changes in corresponding retinal layers

To explore the relationships between vessel density (VD) in the retinal vascular plexuses with the thickness and structural changes of their corresponding retinal layers in patients with diabetic retinopathy (DR). Retrospective analysis of 17 eyes of 17 Type 1 diabetes (T1D) patients with severe non...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 14; no. 7; p. e0219164
Main Authors: Lavia, Carlo, Couturier, Aude, Erginay, Ali, Dupas, Bénédicte, Tadayoni, Ramin, Gaudric, Alain
Format: Journal Article
Language:English
Published: United States Public Library of Science 18.07.2019
Public Library of Science (PLoS)
Subjects:
Adult
Angiography
Biology and Life Sciences
Blood vessels
Case-Control Studies
Complications and side effects
Correlation
Density
Diabetes
Diabetes mellitus
Diabetes mellitus (insulin dependent)
Diabetes Mellitus, Type 1 - diagnostic imaging
Diabetes Mellitus, Type 1 - pathology
Diabetic retinopathy
Diabetic Retinopathy - diagnostic imaging
Diabetic Retinopathy - pathology
Edema
Eye (anatomy)
Female
Fluorescein Angiography
Health aspects
Humans
Male
Medical imaging
Medical research
Medicine and Health Sciences
Middle Aged
Ophthalmology
Optical Coherence Tomography
Rarefaction
Research and Analysis Methods
Retina
Retina - diagnostic imaging
Retina - pathology
Retinal Vessels - diagnostic imaging
Retinal Vessels - pathology
Retinopathy
Retrospective Studies
Risk factors
Thickness
Tomography
Tomography, Optical Coherence
Type 1 diabetes
Young Adult
France
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To explore the relationships between vessel density (VD) in the retinal vascular plexuses with the thickness and structural changes of their corresponding retinal layers in patients with diabetic retinopathy (DR). Retrospective analysis of 17 eyes of 17 Type 1 diabetes (T1D) patients with severe non-proliferative or proliferative DR and no current or past macular edema. Seventeen age- and sex-matched healthy subjects were included as controls. Using optical coherence tomography (OCT) and OCT-angiography (OCTA), VD was measured in the superficial vascular plexus (SVP) and deep vascular complex (DVC) that includes the intermediate (ICP) and deep capillary plexuses (DCP), and compared to the retinal thickness (RT) of the inner (from the inner limiting membrane to the inner plexiform layer) and intermediate (inner nuclear and outer plexiform layer) retinal layers. The correlation between the inner and intermediate RT and the VD of the corresponding vascular networks (SVP and DVC, respectively) was assessed. All OCT and OCTA examinations were performed using the RTVue XR Avanti (Optovue, Fremont, CA). The inner RT and VD in all plexuses were significantly reduced in T1D patients compared to healthy subjects. The capillary drop-out patterns were polygonal and well-defined in the SVP while the ICP and DCP showed a more diffuse capillary rarefaction and a VD that varied in the same proportion. The inner RT significantly correlated with VD in the SVP (r = 0.71 in healthy subjects and r = 0.62 in T1D patients, p <0.01). The intermediate RT did not significantly correlate with VD in the DVC. In T1D subjects, OCTA allowed observing different capillary drop-out patterns in the SVP and in the ICP-DCP, with different structural changes in the corresponding retinal layers, suggesting that they should be considered as distinct anatomical and functional entities.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests:Dr. LAVIA: none; Dr. COUTURIER: Allergan (F), Bayer (F), Novartis (F); Dr. ERGINAY: Allergan (F), Zeiss (F), Bayer (F), Optovue (F), Novartis (F); Dr. DUPAS: Bayer (F), Novartis (F), Allergan (F); Pr. TADAYONI: Novartis (F), Bayer (F), Roche (F), Genentech (F), Allergan (F), Zeiss (F), Alcon (F); Pr. GAUDRIC: Novartis (F), Bayer (F), Thrombogenics (F). This does not alter our adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0219164